Helicobacter Pylori Eradication With Berberine Plus Amoxicillin Triple Therapy Versus Bismuth-containing Quadruple Therapy
Efficacy and Safety of Berberine Hydrochloride, Amoxicillin and Rabeprazole Triple Therapy in the First Eradication of Helicobacter Pylori
Sponsor: Xijing Hospital of Digestive Diseases
Listed as NCT04697186, this PHASE4 trial focuses on Chronic Gastritis and Dyspepsia and remains completed. Sponsored by Xijing Hospital of Digestive Diseases, it has been updated 5 times since 2021, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
5 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE4
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE4
-
Feb 2023 — Jul 2024 [monthly]
Completed PHASE4
Status: Enrolling By Invitation → Completed
-
May 2021 — Feb 2023 [monthly]
Enrolling By Invitation PHASE4
Status: Not Yet Recruiting → Enrolling By Invitation
-
Feb 2021 — May 2021 [monthly]
Not Yet Recruiting PHASE4
First recorded
Jan 2021
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Xijing Hospital of Digestive Diseases
For direct contact, visit the study record on ClinicalTrials.gov .